Nyxoah to Present Innovative OSA Treatment at 44th J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Source: Globenewswire
- Conference Presentation: Nyxoah will showcase its innovative treatment for Obstructive Sleep Apnea (OSA) at the J.P. Morgan Healthcare Conference on January 15, 2026, which is expected to attract investor interest and enhance the company's visibility.
- Technological Innovation: The Genio system, a leadless and battery-free neurostimulation therapy, aims to improve the quality of life for OSA patients, aligning with the global demand for novel medical solutions.
- Market Recognition: Since receiving CE marking in 2019, the Genio system has successfully expanded its indications, particularly for Complete Concentric Collapse (CCC) patients, which are contraindicated in competitors' therapies, showcasing its competitive edge.
- Regulatory Approval: Following FDA approval in 2025, the Genio system is now a prescription-only device, further strengthening Nyxoah's legitimacy and market access opportunities in the U.S.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NYXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NYXH
Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 10.41 USD with a low forecast of 5.82 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.890
Low
5.82
Averages
10.41
High
13.00
Current: 4.890
Low
5.82
Averages
10.41
High
13.00
About NYXH
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nyxoah (NYXH) Projects 25% Revenue Growth for Q1 2026
- Revenue Expectations: Nyxoah anticipates approximately €6.3 million in gross revenue for Q4 2025, indicating sustained growth potential in the medical device market, particularly in sleep therapy solutions.
- Cash Position: As of December 31, 2025, Nyxoah expects cash, cash equivalents, and financial assets to total around €47.9 million, providing robust financial support for future investments and operations.
- Quarterly Revenue Guidance: The company projects a 25% increase in U.S. net revenue for Q1 2026 compared to Q4 2025, reflecting rising market acceptance and demand for its products, which could positively impact stock performance.
- Financing Plan: Nyxoah announced a multi-part financing plan totaling up to €84 million, which will provide essential funding for research and development as well as market expansion, further solidifying its competitive position in the industry.
Continue Reading
Nyxoah Expects 348% Q4 Revenue Growth, $5.7M Forecast
- Revenue Growth Expectations: Nyxoah anticipates Q4 2025 revenue to reach €5.7 million, a 348% increase from €1.3 million in the same quarter last year, indicating strong market demand for its Obstructive Sleep Apnea treatments.
- Significant Annual Performance: The company expects full-year 2025 revenue to hit €10 million, up 122% from €4.5 million in 2024, reflecting successful product promotion and increased customer acceptance in the market.
- Strong Cash Position: As of December 31, 2025, Nyxoah expects to hold approximately €47.9 million in cash and cash equivalents, providing ample funding for future R&D and market expansion initiatives.
- FDA Approval and Market Expansion: Nyxoah's Genio system received FDA approval in August 2025, with 145 surgeons trained and 57 accounts activated in the U.S., marking a successful launch and significant growth potential in the American market.
Continue Reading